1. Home
  2. NVR vs ILMN Comparison

NVR vs ILMN Comparison

Compare NVR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NVR Inc.

NVR

NVR Inc.

HOLD

Current Price

$7,385.15

Market Cap

20.5B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$135.14

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVR
ILMN
Founded
1980
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
NVR
ILMN
Price
$7,385.15
$135.14
Analyst Decision
Buy
Hold
Analyst Count
3
16
Target Price
$8,366.67
$116.19
AVG Volume (30 Days)
21.7K
1.8M
Earning Date
01-27-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
456.53
4.46
Revenue
$10,582,633,000.00
$4,288,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.08
P/E Ratio
$16.21
$30.22
Revenue Growth
2.93
N/A
52 Week Low
$6,562.85
$68.70
52 Week High
$8,618.28
$153.06

Technical Indicators

Market Signals
Indicator
NVR
ILMN
Relative Strength Index (RSI) 45.88 64.21
Support Level $7,418.66 $129.29
Resistance Level $7,611.69 $137.09
Average True Range (ATR) 143.28 3.84
MACD -2.29 -0.64
Stochastic Oscillator 16.42 82.09

Price Performance

Historical Comparison
NVR
ILMN

About NVR NVR Inc.

NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: